HALT Fentanyl Act

Bill Number: S. 331
Origin Chamber: Senate
Congress: 119th Congress, Session 1
Policy Area: Crime and Law Enforcement
Status: Became Law
Became Law: Public Law 119-26
Latest Action: 2025-07-16: Became Public Law No: 119-26.
Last Updated: 2026-03-12T15:04:04Z

AI-Generated Summary

Purpose of the Legislation

The HALT Fentanyl Act aims to address the fentanyl overdose crisis by classifying a broad range of fentanyl-related substances as controlled drugs under federal law. It expands restrictions on these substances while simplifying rules for legitimate scientific research, making it easier to study potential treatments or understand their effects.

Key Provisions

Scheduling of Fentanyl-Related Substances: Adds a new category to Schedule I of the Controlled Substances Act (CSA), which lists the most restricted drugs (those with high abuse potential and no accepted medical use). This includes any substance structurally similar to fentanyl through specific chemical changes, such as replacing parts of its molecular structure with other groups (e.g., alkyl or halo groups). Exemptions apply if the substance is already controlled elsewhere or by the Attorney General.
Research Registration Simplifications:
Creates expedited processes for researchers working on Schedule I substances like fentanyl-related ones, especially if funded by or involving the Department of Health and Human Services (HHS), Department of Defense (DoD), or Department of Veterans Affairs (VA), or under an investigational new drug exemption from the FDA.
Allows notifications instead of full applications for registered researchers, with approvals or denials within 30–45 days.
Permits additional researchers in the same institution to work under one registration, with notifications to the DEA (Drug Enforcement Administration).
Enables a single registration for research sites in the same city or county under one organization.
Waives new inspections when adding similar substances to existing research registrations.
Allows ongoing research to continue for up to 90 days after a substance is newly scheduled, with expedited hearings if needed.
Treats small-scale manufacturing (e.g., creating extracts or solutions for testing) as part of research, without needing a separate manufacturing license (excludes growing marijuana).
Requires public transparency on any special DEA procedures for researching specific substances.
Penalties and Enforcement:
Increases criminal penalties for manufacturing, distributing, importing, or exporting fentanyl-related substances, treating them like fentanyl analogues (e.g., up to life in prison for large quantities causing death).
Defines "fentanyl-related substance" consistently across the CSA.
Rulemaking and Applicability:
Directs the Attorney General (via DEA) to issue implementing rules as interim final rules within 6 months, effective immediately, with public comment periods.
Changes apply from the date of enactment, regardless of final rules.
Includes technical fixes to prior laws and a congressional note affirming court interpretations that certain fentanyl variants are illegal analogues.
Reporting Requirement: Mandates a Department of Justice Inspector General report within one year on fentanyl research funded by federal agencies.

Significant Changes to Existing Law

Broadens Drug Controls: Shifts from listing individual fentanyl variants to a "class scheduling" approach, automatically controlling any substance matching the structural definition without needing separate DEA scheduling actions. This closes loopholes where new variants evade bans.
Eases Research Barriers: Previously, Schedule I research required lengthy DEA approvals and separate registrations per person or site. The Act streamlines this with notifications, shared registrations, and no new inspections for similar substances, reducing administrative hurdles (e.g., from months to 30–45 days).
Enhances Penalties: Explicitly includes fentanyl-related substances in high-penalty sections of the CSA and import/export laws, aligning them with fentanyl itself and removing ambiguity about their status as analogues.
Technical Updates: Corrects errors in recent laws (e.g., from the 2022 omnibus spending bill) related to practitioner registrations.

Potential Impacts

On Government Agencies: The DEA gains tools for faster enforcement against emerging fentanyl variants, reducing the need for constant updates to drug lists. HHS, DoD, and VA can accelerate federally funded research on fentanyl's effects or antidotes, potentially speeding up public health responses. An Inspector General report may highlight oversight needs.
On Citizens: Stricter controls could reduce street availability of deadly fentanyl analogues, lowering overdose deaths (fentanyl is a leading cause). However, it may increase penalties for users or small-scale possessors caught with these substances. Easier research could lead to better treatments for opioid addiction or pain management.
On International Relations: Tougher import/export penalties may pressure foreign suppliers (e.g., from Mexico or China) and enhance U.S. cooperation with international partners on drug trafficking, but could complicate legitimate pharmaceutical trade.

Main Stakeholders Affected

Law Enforcement and Regulators: DEA and Justice Department benefit from clearer enforcement tools but must handle more streamlined research approvals.
Researchers and Institutions: Universities, hospitals, and federal agencies (HHS, DoD, VA) gain easier access to Schedule I substances for studies, reducing costs and delays.
Pharmaceutical and Medical Communities: Drug developers can perform small-scale manufacturing for FDA trials without extra licenses, aiding innovation in addiction treatments.
People Impacted by Opioid Crisis: Victims, families, and addiction treatment providers may see indirect benefits from reduced trafficking and better research, though penalties could disproportionately affect low-level offenders in affected communities.
Drug Traffickers and Manufacturers: Face heightened risks of severe penalties, deterring production and distribution of fentanyl variants.

Notable Legal, Constitutional, or Political Implications

Legal Implications: Strengthens prosecutions by clarifying that fentanyl-related substances qualify as controlled "analogues" (chemically similar drugs treated like the original), as affirmed in a 2018 court case (United States v. McCray). The class-scheduling approach prevents "designer drugs" from slipping through cracks, but a "rule of construction" ensures pre-enactment cases aren't retroactively affected. No changes to importation/export rules beyond penalties.
Constitutional Implications: None directly raised; the Act operates within Congress's commerce clause authority to regulate controlled substances. Expedited processes respect due process by allowing hearings and notifications.
Political Implications: Reflects bipartisan urgency on the opioid epidemic (fentanyl deaths exceed 70,000 annually). By balancing enforcement with research facilitation, it appeals to both tough-on-crime and public health advocates, potentially influencing future drug policy debates without major controversies.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Cassidy, Bill [R-LA]

Cosponsors (31)

Sen. Heinrich, Martin [D-NM], Sen. Grassley, Chuck [R-IA], Sen. Marshall, Roger [R-KS], Sen. Young, Todd [R-IN], Sen. Daines, Steve [R-MT], Sen. Rounds, Mike [R-SD], Sen. Capito, Shelley Moore [R-WV], Sen. Schmitt, Eric [R-MO], Sen. Kennedy, John [R-LA], Sen. Gallego, Ruben [D-AZ], Sen. Hassan, Margaret Wood [D-NH], Sen. Cortez Masto, Catherine [D-NV], Sen. Shaheen, Jeanne [D-NH], Sen. King, Angus S., Jr. [I-ME], Sen. Kelly, Mark [D-AZ], Sen. Cornyn, John [R-TX], Sen. Hawley, Josh [R-MO], Sen. Tillis, Thomas [R-NC], Sen. Graham, Lindsey [R-SC], Sen. Cruz, Ted [R-TX], Sen. Britt, Katie Boyd [R-AL], Sen. Blackburn, Marsha [R-TN], Sen. Lee, Mike [R-UT], Sen. Moody, Ashley [R-FL], Sen. McCormick, David [R-PA], Sen. Collins, Susan M. [R-ME], Sen. Sullivan, Dan [R-AK], Sen. Justice, James C. [R-WV], Sen. Ricketts, Pete [R-NE], Sen. Ernst, Joni [R-IA], Sen. Hyde-Smith, Cindy [R-MS]

Recent Actions

2025-07-16: Became Public Law No: 119-26.
2025-07-16: Became Public Law No: 119-26.
2025-07-16: Signed by President.
2025-07-16: Signed by President.
2025-07-08: Presented to President.
2025-07-08: Presented to President.
2025-06-12: Motion to reconsider laid on the table Agreed to without objection.
2025-06-12: On passage Passed by the Yeas and Nays: 321 - 104 (Roll no. 166). (text: 6/11/2025 CR H2625-2627) (Roll call 166)
2025-06-12: Passed/agreed to in House: On passage Passed by the Yeas and Nays: 321 - 104 (Roll no. 166). (text: 6/11/2025 CR H2625-2627) (Roll call 166)
2025-06-12: Considered as unfinished business. (consideration: CR H2806)
2025-06-11: POSTPONED PROCEEDINGS - At the conclusion of debate on S. 331, the Chair put the question on passage of the bill and by voice vote, announced that the ayes had prevailed. Mr. Pallone demanded the yeas and nays and the Chair postponed further proceedings until a time to be announced.
2025-06-11: The previous question was ordered pursuant to the rule.
2025-06-11: DEBATE - The House proceeded with one hour of debate on S. 331.
2025-06-11: Rule provides for consideration of H.R. 884, H.R. 2056, H.R. 2096 and S. 331. The resolution provides for consideration of H.R. 884, H.R. 2056, H.R. 2096, and S. 331 under a closed rule with one hour of general debate for each bill. The resolution provides for one motion to recommit on H.R. 884, H.R. 2056, and H.R. 2096, and one motion to commit on S. 331.
2025-06-11: Considered under the provisions of rule H. Res. 489. (consideration: CR H2625-2633)

Bill Versions

Halt All Lethal Trafficking of Fentanyl Act — issued 2025-06-13 — PDF (9 pages)
Halt All Lethal Trafficking of Fentanyl Act — issued 2025-03-14 — PDF (26 pages)
Halt All Lethal Trafficking of Fentanyl Act — issued 2025-01-30 — PDF (23 pages)
Halt All Lethal Trafficking of Fentanyl Act — issued 2025-03-03 — PDF (46 pages)